ClinicalTrials.Veeva

Menu

Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant

R

restor3d

Status

Terminated

Conditions

Osteoarthritis

Treatments

Device: iUni® Unicompartmental Knee Resurfacing Device

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

Study is prospective and multi-center. Study will include 100 to 200 patients across up to 20 sites.The study sites will be located in the United States.The study objective is to evaluate the safety and performance of the ConforMIS iUni® Unicompartmental Knee Resurfacing Device in patients with single compartment osteoarthritis.

Full description

The iUni G2 Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The study subjects will be followed for 10 years post implant. The study objective is to evaluate the safety and performance of the ConforMIS iUni® Unicompartmental Knee Resurfacing Device in patients with single compartment osteoarthritis. The iUni is a patient-specific unicompartmental resurfacing device designed from the patient's unique anatomy using proprietary software which interprets data from the patient's CT scan. The patient matched implant design is then coupled with unique patient-matched disposable instrumentation designed using the same CT data and software. The follow-up visit schedule will include visits at 6 weeks, 6 months (optional), 1 year, 2 years, 5 years and 10 years post implant.The remaining follow-up data collected at years 3, 4, 6, 7, 8, and 9 may be collected via phone call/email and does not require a subject visit to the site.The study sites will be located in the United States.

Enrollment

120 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Clinical condition included in the approved Indications For Use
  2. Unicompartmental osteoarthritis of the medial or lateral tibiofemoral compartment
  3. Willingness to participate in the clinical study, to give informed consent and to attend all follow-up visits
  4. > 18 years of age

Exclusion criteria

  1. Simultaneous bilateral procedure required
  2. BMI > 35
  3. Treatment for cancer within the past 5 years, with the exception of skin cancer
  4. Poorly controlled diabetes
  5. Neuromuscular conditions which prevent patient from participating in study activities
  6. Active local or systemic infection
  7. Immunocompromised
  8. Fibromyalgia or other general body pain related condition
  9. Advanced tricompartmental osteoarthritis
  10. Symptomatic patellofemoral disease
  11. Rheumatoid arthritis or other forms of inflammatory joint disease
  12. Loss of bone or musculature, osteoporosis, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated to an extent that the procedure is unjustified
  13. Advanced loss of osteochondral structure on the affected femoral condyle
  14. Compromised ACL, PCL or collateral ligament
  15. Severe (>15º) fixed valgus or varus deformity
  16. Extension deficit > 15 º
  17. Prior history of failed implant surgery of the joint to be treated
  18. Unwilling or unable to comply with study requirements
  19. Participation in another clinical study which would confound results

Trial design

120 participants in 1 patient group

open label
Description:
iUni® Unicompartmental Knee Resurfacing Device
Treatment:
Device: iUni® Unicompartmental Knee Resurfacing Device

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems